Publications - Tetyana V. Masyuk, Ph.D.

Back to research profile

1. Tietz Bogert PS, Huang BQ, Gradilone SA, Masyuk TV, Moulder GL, Ekker SC, Larusso NF. The Zebrafish as a Model to Study Polycystic Liver Disease. Zebrafish. 2013 May 13. [Epub ahead of print]
   View PubMed
2. Masyuk AI, Masyuk TV, Larusso NF. Exosomes in the Pathogenesis, Diagnostics and Therapeutics of Liver Diseases. J Hepatol. 2013 Apr 01. [Epub ahead of print]
   View PubMed
3. Tabibian JH, Masyuk AI, Masyuk TV, O'Hara SP, LaRusso NF. Physiology of cholangiocytes. Comprehensive Physiology. 2013 Jan; 3(1):541-65.
4. Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Gradilone SA, Huang B, Masyuk AI, Hogan MC, Torres VE, Larusso NF. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology. 2012 Nov 21. [Epub ahead of print]
   View PubMed
5. Wang X, Ye H, Ward CJ, Chu JY, Masyuk TV, Larusso NF, Harris PC, Chow BK, Torres VE. Insignificant effect of secretin in rodent models of polycystic kidney and liver disease. Am J Physiol Renal Physiol. 2012 Oct; 303(7):F1089-98. Epub 2012 Jul 18.
   View PubMed
6. Hogan MC, Masyuk TV, Page L, Holmes DR 3rd, Li X, Bergstralh EJ, Irazabal MV, Kim B, King BF, Glockner JF, Larusso NF, Torres VE. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant. 2012 Sep; 27(9):3532-9. Epub 2012 Jul 06.
   View PubMed
7. Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Masyuk AI, Gradilone SA, Gajdos GB, Chandok N, Bakeberg JL, Ward CJ, Ritman EL, Kiyokawa H, LaRusso NF. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. Gastroenterology. 2012 Mar; 142(3):622-633.e4. Epub 2011 Dec 07.
   View PubMed
8. Thabut D, Routray C, Lomberk G, Shergill U, Glaser K, Huebert R, Patel L, Masyuk T, Blechacz B, Vercnocke A, Ritman E, Ehman R, Urrutia R, Shah V. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology. 2011 Aug; 54(2):573-85. Epub 2011 Jun 26.
   View PubMed